Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery
Year: 2017
Type: review
Abstract: Recent advances in metabolomic and genome mining approaches have uncovered a poorly understood metabolome that originates solely or in part from bacterial enzyme sources. Whether living on exposed surfaces or within our intestinal tract, our microbial inhabitants produce a remarkably diverse set of natural products and small molecule metabolites that can impact human health and disease. Highlighted here, the gut microbe-derived metabolite trimethylamine N -oxide has been causally linked to the development of cardiovascular diseases. Recent studies reveal drugging this pathway can inhibit atherosclerosis development in mice. Building on this example, we discuss challenges and untapped potential of targeting bacterial enzymology for improvements in human health.
Source: Journal of Biological Chemistry
Authors: J. Mark Brown, Stanley L. Hazen
Institution: Cleveland Clinic
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,430
Awards: G3758830673, G4280229963, Diet, Gut Microbiota, and Heart Failure, Oxidation in Inflammation and Cardiovascular Disease, G618166607, G7014634524, G7520014791, G7893260354, Gut Flora metabolism of dietary carnitine and cardiovascular disease, G8259519777, Enzymatic Control of Trimethylamineoxide (TMAO)Induced Atherosclerosis, Alcohol and tissue injury, from mechanisms to treatments
OpenAlex ID: W2605025237